Two studies published in 2026 link ADHD to a higher average risk of death and self-harm, and suggest that the period before treatment starts is the most vulnerable time. These are associations across large populations, not individual predictions: any one person's risk of death remains low, and the researchers' main message is about the value of timely diagnosis and support.
- Mortality: a meta-analysis published on 19 October 2026 in JAMA Network Open (19 studies, almost 16 million people) found that the risk of death was on average 1.71 times higher in people with ADHD.
- Self-harm: in a BMJ Mental Health study of 461,024 people prescribed ADHD medication in five health systems, the risk was highest in the 90 days before treatment started.
- The limits: both are observational studies, which show links, not causes.
If you are having thoughts of suicide or of harming yourself, please reach out now: these feelings can pass, and help is available. In the US, call or text 988. In the UK and Ireland, call Samaritans free on 116 123, day or night. Elsewhere, or if you are in immediate danger, call your local emergency number.
Study 1: a higher risk of death, on average
This systematic review and meta-analysis, by researchers at the University of Liverpool, University College London (UCL), King's College London and other institutions, pooled 19 observational studies comparing people with and without ADHD: 15.9 million participants of all ages in the United States, Canada, Sweden, Taiwan, the UK, Finland and Denmark. Pooled results (hazard ratios with 95% confidence intervals):
- Death from any cause: 1.71 (1.31 to 2.24), 9 studies.
- Suicide: 1.89 (1.21 to 2.95), 5 studies.
- Injury, unintentional or intentional: 1.55 (1.22 to 2.00), 4 studies.
- Natural causes (illness): 1.27 (1.16 to 1.38), 3 studies.
Among people with ADHD, taking ADHD medication was associated with lower mortality (0.75; 0.64 to 0.87). But this rests on only 3 studies, and the authors stress that it is not evidence of a protective effect: people who receive treatment may differ from those who do not (access to care, living conditions, severity).
Other limits: results varied widely between studies, samples were mostly male, and diagnostic practices differ between countries. The work was funded by the UK's Medical Research Foundation, which had no role in it, and none of the authors reported ties to the pharmaceutical industry.
Study 2: the 90 days before treatment, a vulnerable window
Led by Aston University in Birmingham with UCL and the University of Hong Kong, this study was published online on 12 September 2026 in BMJ Mental Health and announced by the university on 22 October. It used health records from Hong Kong, New Zealand, South Korea, Taiwan and the UK between 2001 and 2020. Of 461,024 people aged 6 and over with at least one ADHD medication prescription, 6,847 had a recorded self-harm episode, whatever the intent, and they formed the study group.
The design, called a self-controlled case series, compares each person with themselves: the self-harm rate in certain periods is set against the same person's periods without treatment. This removes stable differences between people, but not things that change over time. Pooled results (incidence rate ratios, 95% confidence intervals):
- 90 days before starting treatment: 2.58 (2.12 to 3.13), the highest level.
- First 90 days of treatment: 1.78 (1.23 to 2.57).
- Later treatment: 1.27 (1.01 to 1.60).
The pattern held in all five databases, in women and men, and for stimulants (such as methylphenidate) as well as non-stimulants (such as atomoxetine). The authors say this does not support the idea that these medicines are the main driver of self-harm; the pre-treatment peak may reflect unmanaged ADHD-related difficulties. They also caution that the later drop should not be credited to medication alone, since the assessment, counselling and closer follow-up that come with it may also help. As Dr Adrienne Chan, who led the study with Professor Ian Wong, put it, "many people are already at their highest risk before treatment even begins".
Limits: participants were often young (average age 9 to 25 depending on the database), only episodes recorded by health services were counted, and the design cannot say how common self-harm is in ADHD. The study was funded by the Research Grants Council of Hong Kong; several authors declared grants or fees from pharmaceutical companies, including makers of ADHD medicines, outside this work.
Relative versus absolute risk: what "1.71" means
A ratio of 1.71 is a relative risk: on average, deaths were about 70% more frequent in groups with ADHD. It does not tell you how many people are affected. When the starting risk is low, a large relative increase is still a small number in absolute terms.
One of the included studies, a Danish national cohort of 1.92 million people (32,061 with ADHD) published in The Lancet in 2015, gives a sense of scale: 5.85 deaths per 10,000 people per year of follow-up among those with ADHD, against 2.21 among those without. Put differently, more than 99.9% of people with ADHD were alive at the end of each year of follow-up. These figures apply to that cohort, followed from age one, and do not transfer directly to other countries or age groups.
Why the extra risk? What the researchers suggest
- Accidents and injuries: differences in attention and impulse control, and a higher risk of serious road traffic accidents.
- Co-occurring conditions: depression, anxiety and substance use, all more common with ADHD. ADHD also often co-occurs with autism, which could explain part of the link.
- Physical health: smoking, diet, sleep problems, and difficulty sticking with long-term medical treatment.
- Social factors: exclusion, disadvantage, stigma and lower educational attainment on average.
- Diagnosis and access to care: both teams stress timely diagnosis and treatment. The Aston team suggests the pre-treatment period may involve worsening difficulties, other emerging conditions or significant stress.
What these studies do not say
- They do not prove that ADHD itself causes deaths: other, poorly measured factors may play a part.
- They do not say your life will be shorter: an average across millions of people is not an individual fate.
- They prove neither that ADHD medicines protect nor that they cause self-harm.
- The data come from North America, the Nordic countries, the UK, East Asia and New Zealand; health systems elsewhere may differ.
These findings are not a reason to start, stop or change any treatment on your own: if you have questions, talk to your doctor.
What this means for adults with ADHD
The useful message is less "ADHD is dangerous" than "ADHD deserves to be recognised and supported".
- Get your difficulties recognised. Our adult ADHD self-assessment questionnaire (ASRS v1.1) can help you put words and examples to what you experience before you talk to your doctor. The result is not a diagnosis. For the wider picture, see ADHD in Adults: The Complete Science-Based Guide (2026).
- Do not wait alone. If your mood gets worse while you wait for an assessment, tell your GP or family doctor rather than waiting for the specialist appointment. More ideas in Waiting Years for an ADHD or Autism Assessment? What You Can Do Meanwhile.
- Mention what comes with ADHD. Depression, anxiety, alcohol or drug use, sleep problems: these can be treated, and talking about them is part of good care.
- Keep perspective. For an overview of research across the life course, see ADHD in Childhood: The Long-Term Adult Outcomes Research Reveals.
Frequently asked questions
Does ADHD shorten life expectancy?
On average, studies find higher mortality in people with ADHD, mainly from accidents, injuries and suicide. But the absolute risk remains low, and several of the factors involved (co-occurring conditions, access to care, living conditions) can be addressed. It is not a prediction about you.
Do ADHD medicines increase the risk of self-harm?
The BMJ Mental Health study does not point that way: the risk was highest before treatment and lower afterwards, in all five health systems. The authors recommend careful monitoring before and during treatment. For your own situation, talk to your doctor.
Does treatment reduce mortality?
The meta-analysis found an association with about 25% lower mortality, but based on only 3 studies, and its authors stress that this is not proof of a protective effect.
Can an online questionnaire tell me if I have ADHD?
No. A self-assessment questionnaire helps you take stock and prepare for an appointment; only a qualified clinician can make a diagnosis.
Who can I talk to if I am going through a very hard time?
In the US, call or text 988. In the UK and Ireland, Samaritans answer free on 116 123, 24 hours a day. Elsewhere, or in an emergency, call your local emergency number. Your doctor can also see you and point you to support.
References: Corrigan L, Heywood L, Stewart GR, O'Nions E, Shelford H, Stott J, John A (2026). Mortality Among People With Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. JAMA Network Open 9(10):e2639448, published 19 October 2026. doi:10.1001/jamanetworkopen.2026.39448 (systematic review and meta-analysis of 19 observational studies, 15,920,970 participants) | Chan AYL, Beyene K, Park S, Shen CY, Yuen ASC, et al., Man KKC, Wong ICK (2026). ADHD medication use and risk of self-harm: a multinational self-controlled case series study. BMJ Mental Health 29(1):e302819, published online 12 September 2026. doi:10.1136/bmjment-2026-302819 (self-controlled case series, 5 databases, 461,024 people prescribed ADHD medication, of whom 6,847 had a self-harm episode) | Dalsgaard S, Østergaard SD, Leckman JF, Mortensen PB, Pedersen MG (2015). Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. The Lancet 385(9983):2190-2196. doi:10.1016/S0140-6736(14)61684-6 (Danish national cohort, 1.92 million people including 32,061 with ADHD) | UCL, 19 October 2026: ADHD linked to higher mortality but medication may help | Aston University, 22 October 2026: Aston University-led international study finds ADHD medication unlikely to raise risk of self-harm | 988 Suicide and Crisis Lifeline (US) | Samaritans (UK and Ireland)